Login
Companies $INO
$1.39 -$0.01 (0.71%) After hours
INOVIO PHARMACEUTICALS, INC. logo

INOVIO PHARMACEUTICALS, INC.

inovio.com

What Do They Do?

Develops DNA medicines and delivery devices intended to treat or protect people from HPV-associated diseases, cancer and infectious diseases.

How Do They Make Money?

INOVIO has not generated revenue from product sales; it earns money from license fees, milestone revenue, and collaborative research and development agreements and contracts.

FY2025 revenue

Who Are Their Customers?

ApolloBio is a collaborator and accounted for all of INOVIO's revenue.

Customers above 10% of revenue, FY2025
of revenue from one customer
FY2024: 100% from one customer

Do Revenues Turn Into Profits?

No. It lost $84.9M in FY2025.

Operating income, FY2025
−132871% of revenue
▲ +23% (Loss) vs FY2024 (−$112.4M, −51617%)
Net income, FY2025
−130000% of revenue
▲ +21% (Loss) vs FY2024 (−$107.3M, −49254%)
Free cash flow, FY2025
−136074% of revenue
▲ +15% (Loss) vs FY2024 (−$104.6M, −48019%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
vs $0 in Q3 FY2025
  • Oct 30, 2026 FDA grants accelerated approval for VOCERYQ Approval is for reducing surgery frequency in adults with RRP, and continued approval may depend on confirmatory studies.

Shrinking. Revenue fell 96% in 4 years, from $1.8M in FY2021 to $65.3K in FY2025, about 56% a year.

Who Do They Compete With?

Competes with Merck, GlaxoSmithKline, Precigen, Nykode, Cytovation, AstraZeneca, Bristol-Myers Squibb, MimiVax, AbbVie, BioNTech, Gilead, Janssen Pharmaceuticals, Moderna, Novartis, Pfizer, Roche, Sanofi-Aventis, Agenus, AIVITA, and Barinthus Biotherapeutics

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support